Skip Navigation

European Journal of Heart Failure 2000 2(1):19-21; doi:10.1016/S1388-9842(00)00059-3
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cleland, J. G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cleland, J. G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2000 European Society of Cardiology

Implantable left ventricular assist systems: clinical trials

John G.F. Clelanda,*, Paul Mohacsib, Richard L.W. Murphyc on behalf of the Study Group on Advanced Heart Failure of the Working Group on Heart Failure

a Department of Cardiology, University of Hull Kingston upon Hull, UK
b Cardiology Department, University Hospital CH-3010, Bern, Switzerland
c Study Group on Advanced Heart Failure Secretariat CBC Oxford, 9 Napier Court, Abingdon Science Park, Abingdon, Oxon OX14 3YT, UK

* Corresponding author. Tel.: +44-1482-624087; fax: +44-1482-624085.

Received December 6, 1999; Revised December 23, 1999; Accepted December 23, 1999

The first 10% of the full text of this article appears below.


   1. Introduction
 
Implantable left ventricular assist systems (LVASs) have recently given encouraging results in advanced heart failure (AHF). Controlled comparative trials of LVASs vs. medical therapy could confirm these results, but there are special considerations for such studies [1]. AHF patients and their physicians are reluctant to accept randomisation because, for many (younger) patients who are clearly going to die within days, they are reluctant to refuse . . . [Full Text of this Article]


   2. INNOVAT
 

   3. REMATCH
 

   4. Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
A. A. Louis, I. R. Manousos, A. P. Coletta, A. L. Clark, and J. G.F. Cleland
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH
Eur J Heart Fail, January 1, 2002; 4(1): 111 - 116.
[Abstract] [Full Text] [PDF]